Eiger BioPharmaceuticals (EIGR) Revenue & Revenue Breakdown


OverviewOwnershipFinancialsChart

Eiger BioPharmaceuticals Revenue Highlights


Latest Revenue (Y)

$15.77M

Latest Revenue (Q)

$3.80M

Main Segment (Y)

Product

Eiger BioPharmaceuticals Revenue by Period


Eiger BioPharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$15.77M16.98%
2022-12-31$13.48M11.05%
2021-12-31$12.14M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-06-30--

Eiger BioPharmaceuticals generated $15.77M in revenue during NA 2023, up 16.98% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Eiger BioPharmaceuticals Revenue by Quarter

DateRevenueChange
2023-12-31$3.80M18.51%
2023-09-30$3.21M-30.89%
2023-06-30$4.64M12.75%
2023-03-31$4.12M52.74%
2022-12-31$2.70M-33.00%
2022-09-30$4.02M-1.64%
2022-06-30$4.09M53.05%
2022-03-31$2.67M-20.45%
2021-12-31$3.36M10.56%
2021-09-30$3.04M44.92%
2021-06-30$2.10M-42.48%
2021-03-31$3.65M100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30--

Eiger BioPharmaceuticals generated $3.80M in revenue during Q4 2023, up 18.51% compared to the previous quarter, and up 94.51% compared to the same period a year ago.

Eiger BioPharmaceuticals Revenue Breakdown


Eiger BioPharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22
Product$12.73M
Other Revenue$750.00K

Eiger BioPharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (94.44%), and Other Revenue (5.56%).

Quarterly Revenue by Product

Product/ServiceJun 23Mar 23Dec 22Sep 22Jun 22
Other Revenue$250.00K--$750.00K-
Product$4.39M$4.12M$2.70M$4.02M$3.34M

Eiger BioPharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Product (94.62%), and Other Revenue (5.38%).

Eiger BioPharmaceuticals Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22
Product$4.12M$2.70M$4.02M$3.34M
Other Revenue---$750.00K

Eiger BioPharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: Product (100.00%).

Eiger BioPharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
CHRSCoherus BioSciences$257.24M$64.98M
SPROSpero Therapeutics$96.73M$10.20M
ETONEton Pharmaceuticals$31.64M$9.07M
HOWLWerewolf Therapeutics$19.94M$742.00K
EIGREiger BioPharmaceuticals$15.77M$3.80M
SPRBSpruce Biosciences$10.09M$1.61M
APLTApplied Therapeutics$9.99M$190.00K
BOLTBolt Biotherapeutics$7.88M$1.27M
FUSNFusion Pharmaceuticals$2.07M-
LYRALyra Therapeutics$1.56M$598.00K
UNCYUnicycive Therapeutics$675.00K-
FNCHFinch Therapeutics Group$107.00K-
XFORX4 Pharmaceuticals-$563.00K
GRCLGracell Bio--
DAWNDay One Biopharmaceuticals-$20.07M
CNTBConnect Biopharma--
CINGCingulate--
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
NLTXNeurogene--
TERNTerns Pharmaceuticals--
NUVBNuvation Bio-$1.44M
ELDNEledon Pharmaceuticals--

EIGR Revenue FAQ


Eiger BioPharmaceuticals's yearly revenue for 2023 was $15.77M, representing an increase of 16.98% compared to 2022. The company's yearly revenue for 2022 was $13.48M, representing an increase of 11.05% compared to 2021. EIGR's yearly revenue for 2021 was $12.14M, representing an increase of 100.00% compared to 2020.

Eiger BioPharmaceuticals's quarterly revenue for Q4 2023 was $3.8M, a 18.51% increase from the previous quarter (Q3 2023), and a 41.06% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $3.21M, a -30.89% decrease from the previous quarter (Q2 2023), and a -20.25% decrease year-over-year (Q3 2022). EIGR's quarterly revenue for Q2 2023 was $4.64M, a 12.75% increase from the previous quarter (Q1 2023), and a 13.49% increase year-over-year (Q2 2022).

Eiger BioPharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 29.90%, and for the last 5 years (2019-2023) was 0%.

Eiger BioPharmaceuticals's revenue streams in c 22 are Product, and Other Revenue. Product generated $12.73M in revenue, accounting 94.44% of the company's total revenue Other Revenue generated $750K in revenue, accounting 5.56% of the company's total revenue

For the fiscal year ending Dec 22, the largest source of revenue of Eiger BioPharmaceuticals was Product. This segment made a revenue of $12.73M, representing 94.44% of the company's total revenue.